Image

North America Taxane Market – Industry Trends and Forecast to 2029

Medical Devices

Image

North America Taxane Market – Industry Trends and Forecast to 2029

  • Medical Devices
  • Published Report
  • Jul 2022
  • North America
  • 350 Pages
  • No of Tables: 94
  • No of Figures: 49

North America Taxane Market, By Type (Paclitaxel, Docetaxel, Cabazitaxel), Drug Type (Generics, Branded), Formulation (Liposomes, Nanoparticles, Polymeric Micelles, Others), Age Group (Adults, Geriatric), Application (Breast Cancer, Non-Small Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Prostate Cancer, Others), End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others) Distribution Channel (Retail Sales, Direct Tender) - Industry Trends and Forecast to 2029.

North America Taxane Market

Market Analysis and Insights

North America taxane market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.7% in the forecast period of 2022 to 2029. Technological advancements in taxane drug treatments, coupled with rising applications of computer-aided diagnosis, are other factors driving the taxane market growth in the forecast period.

North America Taxane Market

North America Taxane Market

However, the high cost associated with the drug and side effects such as blood clots, leucopenia, allergy, diarrhea, and weight loss will restrain the market's growth. Adoption of strategic alliances like partnerships and acquisitions by key market players act as an opportunity for the growth of taxane market.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020

Quantitative Units

Revenue in USD Million, Pricing in USD

Segments Covered

By Type (Paclitaxel, Docetaxel and Cabazitaxel), Drug Type (Branded and Generics), Formulation (Liposomes and Polymeric Micelles Containing Taxanes, Hydrogel Formulations Of Taxanes, Nanoparticle Formulation and Others), Age Group (Adults and Geriatric), Application (Ovarian Cancer, Breast Cancer, Prostate Cancer, Non-Small Cell Lung Cancer and Other), End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, and Others), Distribution Channel (Direct Tender, Retail Sales)

Countries Covered

U.S., Canada, Mexico

Market Players Covered

Viatris Inc., Sandoz International GmbH  ( A Novartis Division),  sanofi-aventis U.S. LLC , Hikma Pharmaceuticals PLC, Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Taxane Healthcare, Bristol-Myers Squibb Company, Fresenius Kabi AG (Subsidiary of Fresenius SE & Co. KGaA ), SAMYANG HOLDINGS CORPORATION., Luye Pharma Group, Elevar Therapeutics, Huiang Pharmaceutical Co Ltd., Shenzhen Main Luck Phar maceuticals Inc., Accord Healthcare, Torrent Pharmaceuticals Ltd., Panacea Biotec, RPG Life Sciences Limited., Aureate Healthcare, Samarth Life Sciences Pvt. Ltd., Cipla Inc., Hetero Healthcare Limited., AqVida GmbH, Ingenus Pharmaceuticals, LLC  among others.

Taxane Market Definition

The taxanes or taxoids are a closely related group of antineoplastic agents that have a unique mechanism of action as mitosis inhibitors and are widely used in the therapy of ovarian, breast, lung, esophageal, prostate, bladder and head and neck cancers. Three taxanes are in clinical use, paclitaxel (Taxol: 1992), docetaxel (Taxotere: 1996) and cabazitaxel (Jevtana: 2010). Taxanes are anticancer drugs that interfere with microtubule function, causing changes in mitosis and cellular death. Paclitaxel (Taxol) was first isolated from a yew tree, a small evergreen coniferous tree with a slow growth rate. As paclitaxel was initially scarce, docetaxel (Taxotere), a semisynthetic analogue of paclitaxel derived from the needles of the European yew tree Taxus baccata, was created. Docetaxel differs from paclitaxel in two chemical locations, making it more water soluble. Cabazitaxel is also a semisynthetic analogue of natural taxoids and was developed for its lack of affinity for P-glycoprotein, a common mediator of docetaxel resistance.

Furthermore, increasing use of taxane drugs due to rising prevalence of chronic diseases, surging prevalence of cancer, and increasing investment for healthcare infrastructure. These factors increase in the demand for taxane market has encouraged the key market players to implement newer technologies and strategies through product launches, acquisition, strategies and agreements.

Taxane Market Dynamics                              

Drivers

  • The rise in incidence of cancer

Cancer has a major impact on society in the United States and worldwide. Cancer statistics describe what happens in large groups of people and provide a picture in time of the burden of cancer on society. Taxol, an antimitotic agent, used to treat cancer, blocks cancer cell growth by stopping cell division, resulting in cell death.

According to National Cancer Institute (NCI), a funded clinical trial found that 30 percent of patients with advanced ovarian cancer responded positively to taxane treatment. In clinical practice, the taxane is now standard therapy in metastatic breast cancer. Today, taxol is on the World Health Organization's Model List of Essential Medicines, a cytotoxic drug that kills cancer cells. It treats breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, and AIDS-related Kaposi sarcoma.

  • The funding by the government and investment in research and development

Despite the established effectiveness of pharmacotherapies for treating opioid use and alcohol disorders, limitations to the implementation of taxane by specialty treatment programs have been observed. Certain attention needs to be paid to specific sources for funding, organizational structure, and workforce resources, making a long-term investment that aligns the payment with the potential future beneficiaries. The issues around sustainability, productivity, and patient impact of drug development have never been and will not simply be a product of industry.

The funding by the government would result in the patient's safety, cost-savings. In addition, hospitals and healthcare agencies would administer this treatment at a lower price through collaboration with government organizations. Hence the advancements in research and development activities and funding by the government are expected to drive the market growth.

Restraint

  • Side effects of drugs incurred with the taxane drugs

Taxanes belong to a class of diterpenes. Taxane drugs (paclitaxel and docetaxel) are used as chemotherapeutic agents. Due to ongoing clinical trials, research studies, type of cancer, type of treatment plan, and drug dosage, the present high cost is expected to show a descending trend in the future. Taxane drugs are most effective for treating breast and prostate cancer. However, certain side effects have been reported. The adverse complications or side effects reported would lead to a decline in sales of the taxane drugs, which would limit the sales of the drugs. In addition, it would affect the reliability of manufacturers involved in this market and hence be expected to restrain the market growth.

Opportunity

  • Strategic initiative by market players

The demand for taxane market has increased in the U.S. and Europe owing to the timely treatment of alcohol and opioid disorders. These favorable factors enhance the need for taxane, and to achieve the market demand, minor and major market players are utilizing various strategies.

The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.

These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping the companies grow and improve the company's product portfolios, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players provide an opportunity to help in future growth and drive market growth.

Challenge

  • The lack of skilled professionals required for taxane drug treatment

The lack or shortage of skilled expertise would challenge the pace of recovery and growth in one place. Often the unemployed people in one place have skills that are in short supply elsewhere. Moreover, rapid technological advancement in this field also leads to a lack of expertise.

Physician supply is a term used to describe the number of trained physicians working in a healthcare system or labor market. It is dependent on the number of graduates and the retention rates of the profession. The physician shortage is a growing concern in many countries around the world.

The World Health Organization (WHO) estimated a global shortage of 4.3 million physicians, nurses, and other health professionals. Despite the strong evidence for the effectiveness of drugs in reducing morbidity and mortality, increasing treatment retention, and improving well-being for individuals with taxane, numerous barriers prevent broader access to taxane drug-based treatment.

Moreover, technological advancement is another aspect that leads to the increased demand for skilled professionals. Neurologists report significant unmet supportive care needs and barriers in their centers, with only a small minority rating themselves as competently providing supportive care. There is an urgent need for the education of professionals for the treatment of dementia and procuring available supportive care resources. Lack of trained and experienced professionals and persistent skill gaps limit the employability prospects and access to quality jobs. Therefore, it is apparent that the availability of professionals with adequate skills is challenging the market growth.

Post COVID-19 Impact on Taxane Market

COVID-19 has resulted in a substantial increase in demand for medical supplies from healthcare professionals and the general public for precautionary measures. Manufacturers of these items have an opportunity to take advantage of the increased demand for medical supplies by ensuring a steady supply of personal protective equipment on the market. COVID-19 is anticipated to have a big impact on the taxane market.

Recent Developments

  • In November 2022, Viatris Inc. and Biocon Biologics Ltd. announced the U.S. launch of interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. Both biosimilar products are available in vial and prefilled pen presentations and are interchangeable for the reference brand, LANTUS (insulin glargine), allowing for substitution at the pharmacy counter. Viatris is committed to improving patient access to sustainable, quality and more affordable healthcare. This has helped the company to grow their product portfolio.
  • In May 2022, Sandoz, a global leader in generic and biosimilar medicines, announced the U.S. launch of its generic pirfenidone, the first AB-rated (fully substitutable) equivalent to Genentech’s Esbriet, to treat patients with idiopathic pulmonary fibrosis (IPF). This prescription oral medicine is immediately available to patients via specialty pharmacies, with a $0 co-pay program for eligible patients. Sandoz is putting patients first by expanding access to generic pirfenidone for those with this rare disease, who will benefit from a more affordable, yet equally effective treatment. This has helped the company to grow its market position and business.

Taxane Scope and Market Size

Taxane market is segmented based on type, drug type, formulation, age group, application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the Difference in your target markets.

By Type

  • Paclitaxel
  • Docetaxel
  • Cabazitaxel

On the basis of type, the North America taxane market is segmented into paclitaxel, docetaxel and cabazitaxel.

By Application

  • Ovarian Cancer
  • Breast Cancer
  • Prostate Cancer
  • Non-small Cell Lung Cancer
  • Other

On the basis of application, the North America taxane market is segmented into ovarian cancer, breast cancer, prostate cancer, non-small cell lung cancer and others.

By Drug Type

  • Generics
  • Branded

On the basis of drug type, the North America taxane market is segmented into branded and generics.

By Formulation

  • Liposomes
  • Nanoparticles
  • Polymeric Micelles
  • Others

On the basis of formulation, the North America taxane market is segmented into liposomes, nanoparticles, polymeric micelles and others.

By Age Group

  • Adult
  • Geriatric

On the basis of age group, the North America taxane market is segmented into adults and geriatric.

By End User

  • Hospitals
  • Ambulatory surgical centers
  • Specialty clinics
  • Others

On the basis of end user, the North America taxane market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others.

By Distribution Channel

  • Direct tender
  • Retail Sales

Taxane Market

On the basis of distribution channel, the North America taxane market is segmented into direct tender, retail sales.

North America Taxane Market Regional Analysis

The taxane market is analyzed and market size information is provided by type, drug type, formulation, age group, application, end user and distribution channel.

The countries covered in the taxane market report are U.S., Canada, Mexico.

In 2022, U.S. is dominating due to the presence of key market players along the largest consumer market with high GDP. U.S is expected to grow due to rise in technological advancement in drug treatments.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Taxane market also provides you with detailed market analysis for every country growth in healthcare industry. Moreover, it provides detailed information regarding healthcare services and treatments, impact of regulatory scenarios, and trending parameters regarding Taxane Market.

Competitive Landscape and Taxane Market Share Analysis

Taxane market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to taxane drugs.

The major companies which are dealing in the taxane market are Viatris Inc., Sandoz International GmbH  (A Novartis Division),  sanofi-aventis U.S. LLC , Hikma Pharmaceuticals PLC, Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Taxane Healthcare, Bristol-Myers Squibb Company, Fresenius Kabi AG (Subsidiary of Fresenius SE & Co. KGaA), SAMYANG HOLDINGS CORPORATION., Luye Pharma Group, Elevar Therapeutics, Huiang Pharmaceutical Co Ltd., Shenzhen Main Luck Phar maceuticals Inc., Accord Healthcare, Torrent Pharmaceuticals Ltd., Panacea Biotec, RPG Life Sciences Limited., Aureate Healthcare, Samarth Life Sciences Pvt. Ltd., Cipla Inc., Hetero Healthcare Limited., AqVida GmbH, Ingenus Pharmaceuticals, LLC  among others.

Strategic alliances like mergers, acquisitions and agreement by the key market players are further expected to accelerate the growth of taxane drugs.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company footprints in the taxane market which also provides the benefit for organization’s profit growth.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, North America vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.


SKU-

TABLE 1 NORTH AMERICA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 2 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA DOCETAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA CABAZITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA BREAST CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA NON-SMALL LUNG CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA PANCREATIC CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA OVARIAN CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA PROSTATE CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 NORTH AMERICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 NORTH AMERICA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 17 NORTH AMERICA GENERICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 NORTH AMERICA BRANDED IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 NORTH AMERICA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 20 NORTH AMERICA LIPOSOMES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 NORTH AMERICA NANOPARTICLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 NORTH AMERICA POLYMERIC MICELLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 NORTH AMERICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 NORTH AMERICA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 25 NORTH AMERICA ADULT IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 NORTH AMERICA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)

TABLE 27 NORTH AMERICA GERIATRIC IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 NORTH AMERICA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)

TABLE 29 NORTH AMERICA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 30 NORTH AMERICA HOSPITALS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 NORTH AMERICA SPECIALTY CLINICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 NORTH AMERICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 NORTH AMERICA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 35 NORTH AMERICA RETAIL SALES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 NORTH AMERICA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 37 NORTH AMERICA DIRECT TENDER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 38 NORTH AMERICA TAXANE MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 39 NORTH AMERICA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 40 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 41 NORTH AMERICA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 42 NORTH AMERICA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 43 NORTH AMERICA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 44 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)

TABLE 45 NORTH AMERICA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)

TABLE 46 NORTH AMERICA CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)

TABLE 47 NORTH AMERICA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 48 NORTH AMERICA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)

TABLE 49 NORTH AMERICA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)

TABLE 50 NORTH AMERICA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 51 NORTH AMERICA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 52 NORTH AMERICA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 53 U.S. TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 54 U.S. PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 55 U.S. TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 56 U.S. TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 57 U.S. TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 58 U.S. PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)

TABLE 59 U.S. DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)

TABLE 60 U.S. CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)

TABLE 61 U.S. TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 62 U.S. ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)

TABLE 63 U.S. GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)

TABLE 64 U.S. TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 65 U.S. TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 66 U.S. RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 67 CANADA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 68 CANADA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 69 CANADA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 70 CANADA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 71 CANADA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 72 CANADA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)

TABLE 73 CANADA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)

TABLE 74 CANADA CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)

TABLE 75 CANADA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 76 CANADA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)

TABLE 77 CANADA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)

TABLE 78 CANADA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 79 CANADA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 80 CANADA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 81 MEXICO TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 82 MEXICO PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 83 MEXICO TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 84 MEXICO TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 85 MEXICO TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)

TABLE 86 MEXICO PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)

TABLE 87 MEXICO DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)

TABLE 88 MEXICO CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)

TABLE 89 MEXICO TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 90 MEXICO ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)

TABLE 91 MEXICO GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)

TABLE 92 MEXICO TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 93 MEXICO TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 94 MEXICO RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials